Text Size

Role of Dopamine Receptors in Primary Focal Dystonias

This study is not yet open for participant recruitment.
Verified August 2011 by Washington University School of Medicine
Sponsor:
Collaborator:
National Institute of Neurological Disorders and Stroke (NINDS)
Information provided by:
Washington University School of Medicine
ClinicalTrials.gov Identifier:
NCT01373840
First received: June 10, 2011
Last updated: August 2, 2011
Last verified: August 2011
History of Changes
  Purpose

Dystonia is a disabling movement disorder characterized by repetitive patterned or sustained muscle contractions causing twisting or abnormal postures that may afflict 250,000 people in the U.S. While the pathophysiology of dystonia remains uncertain the treatment is rather rudimentary. A better understanding of neural mechanisms of dystonias is not only an invaluable prerequisite for developing better treatment options but also a step toward better understanding of the complex network of basal ganglia. In this study I will investigate if there is any difference between the dopamine receptors and dopamine in people with dystonia and healthy subjects.


Condition
Healthy
Focal Dystonias

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Role of Dopamine Receptors in Primary Focal Dystonias

Resource links provided by NLM:

MedlinePlus related topics: Dystonia
U.S. FDA Resources

Further study details as provided by Washington University School of Medicine:

Estimated Enrollment: 40
Study Start Date: September 2011
Estimated Primary Completion Date: April 2016 (Final data collection date for primary outcome measure)
Groups/Cohorts
healthy controls
patients with focal dystonias

  Eligibility

Ages Eligible for Study:   21 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Any healthy control or patient with primary focal dystonia or arm or face.

Criteria

Inclusion Criteria:

  • Age >20
  • Male or Female
  • Any race or ethnicity
  • Primary focal dystonia (arm or cranial)
  • Ability to give informed consent

Exclusion criteria:

  • Family history of dystonia
  • Pregnancy (confirmed with negative urine pregnancy test in women of child bearing potential), breastfeeding
  • Exposure to radiation therapy
  • Any MRI contraindications such as foreign metallic implants, pacemaker, and aneurysm clip etc.
  • History of cardiac disease, uncontrolled hypertension, abnormal EKG during screening phase
  • History of exposure to any drugs affecting dopaminergic systems within the last 6 months (e.g. dopamine receptor blocking agents, cocaine, amphetamine, tetrabenazine, reserpine, L-dopa, dopamine agonists, as they might affect the dopamine receptor binding or endogenous dopamine).
  • Active depression (Beck Depression Inventory_II >14)
  • Cognitive impairment (Mini-Mental State Score <27)
  • CNS active medications such as gabapentin or narcotics, muscle relaxants which might be given for pain in the 3 days prior to study
  • History of stroke, seizure, cerebral palsy, generalized dystonia, parkinsonism, inability to hold head still during the scanning time.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01373840

Contacts
Contact: Pratt Stacey 314-747-5916 pratts@npg.wustl.edu

Locations
United States, Missouri
Washington University Not yet recruiting
St. Louis, Missouri, United States, 63141
Contact: Stacey Pratt     314-747-5916     pratts@npg.wustl.edu    
Principal Investigator: Morvarid Karimi, MD            
Sponsors and Collaborators
Washington University School of Medicine
National Institute of Neurological Disorders and Stroke (NINDS)
Investigators
Principal Investigator: Morvarid Karimi, MD Washington University School of Medicine
  More Information

No publications provided

Responsible Party: Morvarid Karimi, MD, Washington University
ClinicalTrials.gov Identifier: NCT01373840     History of Changes
Other Study ID Numbers: 201102481
Study First Received: June 10, 2011
Last Updated: August 2, 2011
Health Authority: United States: Institutional Review Board

Keywords provided by Washington University School of Medicine:
focal
dystonia
dopamine
receptor

Additional relevant MeSH terms:
Dystonia
Dystonic Disorders
Dyskinesias
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Movement Disorders
Central Nervous System Diseases
Dopamine
Dopamine Agents
Cardiotonic Agents
 Cardiovascular Agents
Therapeutic Uses
Pharmacologic Actions
Sympathomimetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Protective Agents

ClinicalTrials.gov processed this record on May 19, 2013